Possibilities of infection and increase of intraocular pressure after intravitreal application of bevacizumab in treatment of exudative form of AMD.
OBJECTIVE
To establish the frequency increase of intraocular pressure (IOP) and endophthalmitis as well as other complications that may occur after intravitreal application of bevacizumab.


METHODS
The study included 45 patients and 75 eyes with exudative form of senile degeneration of macula lutea, who were treated in the General Hospital "Prim. Dr. Abdulah Nakas" from 2007. and 2010., the patients being aged between 55 and 75 years. The intraocular pressure (IOP) was measured before the application of bevacizumab, and then after 1st, 2nd and 3rd dose, and it was examined by the bio-microscope two days after the application of bevacuzimab.


RESULTS
The average age of the patients treated by bevacizumab was 71.27 years (71 years, 3 months, and 7 days); 28 patients were females and 17 were males. The examination by bio-microscope indicates changes at certain number of patients. After first dose of bevacizumab, there were 9 suffusions of the bulbar conjuctiva in the application area. After the second dose, there were 10 of them, while after the third dose of bevacizumab, there were 5 suffusions and 3 cases of inflammation of the anterior eye segment, anterior uveitis. As for the intraocular pressure, there is no statistically significant difference (p > 0.05) for any measuring period.


CONCLUSIONS
Based on the results achieved in the intravitreal application of bevacizumab in treatment of senile degeneration of macula lutea, we can conclude that there is a possibility of infection after intravitreal application of bevacizumab, but it is minimal when working in a sterile environment. Increased intraocular pressure is possible, but not necessarily to happened after the intravitreal application of the drug.
Department of Ophthalmology, General Hospital Prim dr Abdulah Nakas Sarajevo Kranjceviceva 12, 71 000 Sarajevo Bosnia and Herzegovina. muhovic.bejtic@gmail.com
Jasna
J
Muhovic-Bejtic
Emina
E
Alimanovic-Halilovic
Suzana
S
Pavljasevic
Darko
D
Ler
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000068258:Bevacizumab; D009877:Endophthalmitis / Q000209:etiology*; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab